Delving into the Latest Updates on Paclitaxel Liposomal with Synapse

The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (Cadonilimab) in combination with platinum-containing chemotherapy (Paclitaxel Polymeric Micelles for Injection combined with Cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of Cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with Cadonilimab combined with chemotherapy.

Start Date20 Apr 2025

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

NCT06667908

/ RecruitingPhase 2

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Start Date06 Dec 2024

Sponsor / Collaborator

Johnson & Johnson Enterprise Innovation, Inc.

NCT06010212

/ Not yet recruitingPhase 1/2IIT

Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

This Study is a Single-center, Single-arm, Phase II Clinical Study. The Primary Objective is to Evaluate the Efficacy and Safety of Fruquintinib, Carrelizumab, Paclitaxel Liposomes combined with Nidaplatin as First-line Treatment in Advanced Esophageal squamous cell carcinoma .

Start Date25 Aug 2023

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

100 Clinical Results associated with Paclitaxel Liposomal

Login to view more data

100 Translational Medicine associated with Paclitaxel Liposomal

Login to view more data

100 Patents (Medical) associated with Paclitaxel Liposomal

Login to view more data

24

Literatures (Medical) associated with Paclitaxel Liposomal

01 May 2023·Oncology letters

Carcinoma with signet ring cell differentiation associated with invasive breast cancer: A case report.

Author: Wang, Hongfang ; Ren, Fupeng ; Lai, Yunying ; Hong, Guodai ; Wang, Litao ; Ding, Shun ; Yang, Wei ; Wang, Huan ; Gao, Wenbin

Carcinoma with signet ring cell differentiation is uncommon in patients with invasive breast cancer. Clinical evidence has suggested that the prognosis of this tumor is usually poor if the stage is advanced. The case of a 40-year-old female patient with primary cancer in the right breast accompanied by bilateral neck, axillary, right subclavian and mediastinal lymph node metastases, and left breast metastasis is presented in the current study. The patient developed superior vena cava syndrome and was restricted in lifting the upper right limb when presenting at the Third Affiliated Hospital of Shenzhen University, Shenzhen. The histopathological and immunohistochemical features included ~80% of the tumor cell area having a signet ring cell pattern, exhibiting the phenotype of lobular carcinoma, and ~20% of the tumor cell area exhibiting a ductal carcinoma immunophenotype with neuroendocrine expression The patient received chemotherapy with paclitaxel liposomes and doxorubicin hydrochloride liposomes according to the general guidelines for the treatment of stage IV breast carcinoma. The patient achieved a partial response after 4 cycles of treatment, and then experienced progressive disease in the form of brain metastasis after 6 cycles. Owing to the rarity of carcinoma with signet ring cell differentiation in invasive breast carcinoma, this case report discusses the patient's clinical and histopathological characteristics, and the treatment prognosis.

01 May 2023·Molecular pharmaceutics

Transforming a Toxic Non-Ionizable Drug into an Efficacious Liposome via Ionizable Prodrug and Remote Loading Strategies against Malignant Breast Tumors.

Article

Author: Sun, Mengchi ; Zhang, Ximing ; Sun, Jin ; Chen, Cong ; Feng, Jing ; Zhao, Fangxue ; He, Zhonggui

Liposomes (lipos), one of the most successful nanotherapeutics in the clinic, have made a rapid advance over the past few years. However, still, several challenges exist for lipos for clinical practice, such as low drug loading and premature drug leakage during in vivo circulation. Paclitaxel (PTX), a commonly used first-line drug for cancer chemotherapy, was chosen as the model drug. Due to its non-ionizable and water-insoluble characteristics, the drug-loading efficiency of the marketable PTX lipos, Lipusu, is only 6.76%. Herein, we designed an ionizable PTX prodrug (PTXP) by modifying phenylboronic acid on the C2' hydroxyl group of PTX for the remote loading of liposomal formulations through the pH gradient method. Compared with Lipusu, PTXP lipos displayed a 34% higher loading efficiency and an encapsulation efficiency of approximately 95%. A series of in vitro/vivo experiments indicated that PTXP lipos possess colloidal stability, prolonged blood circulation, high tumor site accumulation, potent anti-tumor effects, and safety. A combination of ionizable prodrugs and remote loading has proved to be an effective and simple strategy to achieve high liposomal encapsulation efficiency of poorly soluble non-ionizable drugs for clinical application.

31 Dec 2022·Drug Delivery

A facile method for anti-cancer drug encapsulation into polymersomes with a core-satellite structure

Article

Author: Cui, Weiwei ; Tang, Qi ; Wang, Zhongjuan ; Zong, Zhitao ; Xu, Congjun ; Sui, Xiaofeng ; Cao, Jiahui ; Lai, Ting ; Tan, Yinqiu ; Xu, Hongchao ; Wang, Cuifeng

Polymersomes possess the self-assembly vesicular structure similar to liposomes. Although a variety of comparisons between polymersomes and liposomes in the aspects of physical properties, preparation and applications have been elaborated in many studies, few focus on their differences in drug encapsulation, delivery and release in vitro and in vivo. In the present work, we have provided a modified direct hydration method to encapsulate anti-cancer drug paclitaxel (PTX) into PEG-b-PCL constituted polymersomes (PTX@PS). In addition to advantages including narrow particle size distribution, high colloid stability and moderate drug-loading efficiency, we find that the loaded drug aggregate in small clusters and reside through the polymersome membrane, representing a unique core-satellite structure which might facilitate the sustained drug release. Compared with commercial liposomal PTX formulation (Lipusu^®), PTX@PS exhibited superb tumor cell killing ability underlain by multiple pro-apoptotic mechanisms. Moreover, endocytic process of PTX@PS significantly inhibits drug transporter P-gp expression which could be largely activated by free drug diffusion. In glioma mice models, it has also confirmed that PTX@PS remarkably eradicate tumors, which renders polymersomes as a promising alternative to liposomes as drug carriers in clinic.

100 Deals associated with Paclitaxel Liposomal

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	China	Luye Pharma Group Ltd.	01 Jan 2003
Non-Small Cell Lung Cancer	China	Luye Pharma Group Ltd.	01 Jan 2003
Ovarian Cancer	China	Luye Pharma Group Ltd.	01 Jan 2003

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Discovery	China	Nanjing Luye Pharmaceutical Co., Ltd.	01 Apr 2009
Advanced gastric carcinoma	Discovery	China	Nanjing Luye Pharmaceutical Co., Ltd.	01 May 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06010212 (ASCO_GI2025) Manual	Phase 2	Advanced Esophageal Squamous Cell Carcinoma First line	11	Fruquintinib + camrelizumab +paclitaxel liposome + nedaplatin	(agsmjcbuuz) = ysitsofwop zummdvggpd (oanwhheoaq, 42.1 - 99.6) View more	Positive	23 Jan 2025